Contents
03 March 2021
Vol 13, Issue 583
Vol 13, Issue 583
Research Articles
- Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
Myct1 inhibition controls tumor angiogenesis, remodels tumor immunity, and improves immunotherapy outcomes in mouse tumor models.
- Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome
Antisense oligonucleotides are efficacious and safe in a humanized mouse model of MECP2 duplication syndrome.
- Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates
Nonhuman primates immunized with adjuvanted stabilized headless HA stem nanoparticles generated influenza-specific broadly neutralizing antibodies.
- BMPR1A maintains skeletal stem cell properties in craniofacial development and craniosynostosis
Stemness of skeletal stem cells in the calvarium is maintained by BMPR1A; disruption depletes stem cells and causes cranial bone fusion.
- Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8+ T cells and improves beta cell function.
- Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer
Blocking MLK4-mediated IL-17RB phosphorylation diminishes downstream signaling and suppresses pancreatic cancer progression and metastasis.
Report
- APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia
APOE4-disrupted intracellular lipid homeostasis in human and yeast cells was reversed by promoting phospholipid synthesis through choline supplementation.
About The Cover
ONLINE COVER Inhibiting Tumor Angiogenesis. This immunofluorescence image of a subcutaneously transplanted Lewis lung carcinoma mouse tumor reveals an abundance of endothelial cells (red; nuclei are stained blue and tumor cells are stained green) that are dependent on Myct1. Kabir et al. investigated mediators of angiogenesis within the tumor microenvironment, finding that Myct1 was expressed in endothelial cells and was critical to tumor growth. The protein product of this gene, MYC Target 1 (MYCT1), was also found to promote an immunosuppressive tumor microenvironment, revealing a dual role for the protein. In combination with immune checkpoint inhibitor treatment, Myct1 knockdown resulted in tumor regression and long-term survival of mice, suggesting that MYCT1 could be a target for cancer therapy. [CREDIT: KABIR ET AL./SCIENCE TRANSLATIONAL MEDICINE]
